News – Page 1104 – Endpoints News

Warring with ex-CEO, options shrinking, Aeterna Zentaris turns to a strategic review

8 years ago

Aclaris bags St. Louis biotech for $20M; Pfizer investing $100M in gene therapy work

8 years ago

Sanofi believes it’s still not too late to become a top player in cancer drug market

8 years ago

Esperion shares bounce up on an effective triplet approach to slashing LDL

8 years ago

Prepping for a rapid-fire launch, Kite Pharma gets a pass from FDA on axi-cel panel review

8 years ago

Roche sells off its struggling IL-13 drug lebrikizumab in $1.4B Dermira deal

8 years ago

Prepping for PhIII cancer study, Sellas reverse merges its way to a public listing

8 years ago

FibroGen shares rocket up on positive PhII data in idiopathic pulmonary fibrosis

8 years ago

FDA slams Vernalis with 2nd CRL in 3 months; Former Shkreli company KaloBios changes name

8 years ago

Updated: Acorda shares surge as a big investor pushes it to the auction block

8 years ago

Mallinckrodt bags late-stage infantile jaundice drug in $425M InfaCare buyout deal

8 years ago

Zynerba goes into meltdown mode as cannabis-derived drug flops in PhII

8 years ago

A small, groundbreaking cardio study pushes MyoKardia to a pivotal showdown — shares soar

8 years ago

GSK déjà vu: Time for a top-down switch as new CEO tries to conquer old R&D demons

8 years ago

Gemphire shares crater after its LDL drug comes up short in PhIIb

8 years ago

Jury finds Martin Shkreli guilty on 3 counts of securities fraud — and he's 'delighted'

8 years ago

Big Pharma veterans at Pfizer, AstraZeneca join the great migration to biotech

8 years ago

Post-merger, Indalo raises $9M; Spark raising $331M; No word on Shkreli’s fate

8 years ago

Aeterna Zentaris claims it booted CEO and then discovered a plot to grab control of its lead asset

8 years ago

Eli Lilly’s new, $1B pain drug racks up another promising round of PhIII pain data

8 years ago

Look out Gilead, AbbVie’s hep C combo comes with stellar data, 8-week regimen and a killer price

8 years ago

Dynavax shares dip after FDA asks for more time to sort out Heplisav post-marketing plan

8 years ago

Trump will sign FDA user fee reauthorization bill, ending threat of agency layoffs

8 years ago

Bristol-Myers beefs up big cancer drug pipeline, buying IFM drugs in $2.3B-plus deal

8 years ago

First page Previous page 1101 1102 110311041105 1106 1107 Next page Last page